first-line treatment

Showing: 1 - 1 of 1 Articles

Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received …